Compounds > 16-alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3-20-dione

16-alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3-20-dione and Sarcoma

16-alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3-20-dione has been researched along with Sarcoma* in 1 studies

Other Studies

1 other study(ies) available for 16-alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3-20-dione and Sarcoma

Article	Year
Estradiol and progesterone receptors in two cases of endometrial stromal sarcoma. Gynecologic oncology, 1984, Volume: 18, Issue:2 The presence of estradiol and progesterone receptors in endometrial stromal sarcoma (ESS) has not been studied previously. Two cases of ESS are reported in which high concentrations of these receptors were found in the tumor tissue. One of these patients had retained the reactivity to hormone treatment for several years. It is suggested that the steroid receptors should be analyzed in all cases of ESS to find tumors with a high receptor content. Hormone treatment of these patients should be part of the primary adjuvant therapy. In cases of a good response the therapy should be prolonged and continued for the rest of the patient's life. Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Estradiol; Female; Humans; Kinetics; Medroxyprogesterone; Middle Aged; Pregnenediones; Receptors, Estradiol; Receptors, Estrogen; Receptors, Progesterone; Sarcoma; Uterine Neoplasms	1984

Article

Year

Estradiol and progesterone receptors in two cases of endometrial stromal sarcoma.

Gynecologic oncology, 1984, Volume: 18, Issue:2

The presence of estradiol and progesterone receptors in endometrial stromal sarcoma (ESS) has not been studied previously. Two cases of ESS are reported in which high concentrations of these receptors were found in the tumor tissue. One of these patients had retained the reactivity to hormone treatment for several years. It is suggested that the steroid receptors should be analyzed in all cases of ESS to find tumors with a high receptor content. Hormone treatment of these patients should be part of the primary adjuvant therapy. In cases of a good response the therapy should be prolonged and continued for the rest of the patient's life.

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Estradiol; Female; Humans; Kinetics; Medroxyprogesterone; Middle Aged; Pregnenediones; Receptors, Estradiol; Receptors, Estrogen; Receptors, Progesterone; Sarcoma; Uterine Neoplasms

1984